Cellular and Molecular Mechanisms of Cancer Metastasis—2nd Edition

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 1058

Special Issue Editor


E-Mail Website
Guest Editor
Head of EXTRO-Lab, Dept. of Therapeutic Radiology and Oncology, Tyrolean Cancer Research Institute, Medical University of Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
Interests: cancer metastasis; cancer stem cells; therapy resistance; molecular mechanisms; cancer microenvironment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Malignant tumors are characterized by the abilities to metastasize, and metastatic spread results in unfavorable prognosis and treatment outcomes. Although metastasis-related pathways are under intensive investigations, the background for the tumor susceptibility to metastasis is still poorly understood. It is also not well known whether carcinoma cells with enhanced metastatic properties reveal an affected treatment sensitivity compared to other malignant cells.

Under current discussion is the fact that a number of specific cellular properties (enhanced invasive and migratory abilities, increased expression of the molecules associated with metastatic spread, metabolic alterations resulting in the enhancement of cancer cell aggressiveness, etc.) and microenvironmental factors (crosstalk between malignant and nonmalignant cells comprising tumors, cytokine and growth factor release by the cells, proinflammatory stimuli, etc.) can contribute to metastatic spread and limit therapy responses.

It is proposed that the following aspects of the subject area be highlighted in this Special Issue:

  • The role of dormancy in metastasis development;
  • Cancer stem cells as a root for metastasis formation;
  • The molecular properties of tumor cells with enhanced metastatic capacities;
  • The molecular mechanisms of organ-specific metastasis;
  • Circulating tumor cells;
  • Therapy-induced metastasis;
  • Tumor metabolism and metastatic spread;
  • The role of the microenvironment (tumor stroma and immune system) in metastatic progression;
  • Exosomes in disease progression;
  • Cytokines contributing to metastatic spread;
  • Metabolic hallmarks of metastasis formation;
  • Diagnostic tools for metastasis detection;
  • Therapeutic approaches to combating metastatic progression.

Prof. Dr. Ira-Ida Skvortsova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 1819 KiB  
Review
Interleukin-1 Receptor-Associated Kinase 1 in Cancer Metastasis and Therapeutic Resistance: Mechanistic Insights and Translational Advances
by Mariana K. Najjar, Munazza S. Khan, Chuling Zhuang, Ankush Chandra and Hui-Wen Lo
Cells 2024, 13(20), 1690; https://doi.org/10.3390/cells13201690 - 12 Oct 2024
Viewed by 514
Abstract
Interleukin-1 Receptor Associated Kinase 1 (IRAK1) is a serine/threonine kinase that plays a critical role as a signaling transducer of the activated Toll-like receptor (TLR)/Interleukin-1 receptor (IL-1R) signaling pathway in both immune cells and cancer cells. Upon hyperphosphorylation by IRAK4, IRAK1 forms a [...] Read more.
Interleukin-1 Receptor Associated Kinase 1 (IRAK1) is a serine/threonine kinase that plays a critical role as a signaling transducer of the activated Toll-like receptor (TLR)/Interleukin-1 receptor (IL-1R) signaling pathway in both immune cells and cancer cells. Upon hyperphosphorylation by IRAK4, IRAK1 forms a complex with TRAF6, which results in the eventual activation of the NF-κB and MAPK pathways. IRAK1 can translocate to the nucleus where it phosphorylates STAT3 transcription factor, leading to enhanced IL-10 gene expression. In immune cells, activated IRAK1 coordinates innate immunity against pathogens and mediates inflammatory responses. In cancer cells, IRAK1 is frequently activated, and the activation is linked to the progression and therapeutic resistance of various types of cancers. Consequently, IRAK1 is considered a promising cancer drug target and IRAK1 inhibitors have been developed and evaluated preclinically and clinically. This is a comprehensive review that summarizes the roles of IRAK1 in regulating metastasis-related signaling pathways of importance to cancer cell proliferation, cancer stem cells, and dissemination. This review also covers the significance of IRAK1 in mediating cancer resistance to therapy and the underlying molecular mechanisms, including the evasion of apoptosis and maintenance of an inflammatory tumor microenvironment. Finally, we provide timely updates on the development of IRAK1-targeted therapy for human cancers. Full article
(This article belongs to the Special Issue Cellular and Molecular Mechanisms of Cancer Metastasis—2nd Edition)
Show Figures

Figure 1

Back to TopTop